Avid Bioservices Inc (CDMO)

[ku]

Bottom line, we have a "new class of drug" that can instruct the immune system to fight all the solid tumor cancers. It is proving itself in multiple indications. The choices are to either file for any path to fast approvals, partner with a company that has the resources to speed up the process of getting it approved in many indications or decide to go it alone in one indication for many years and take all the profit that goes with it. The risk of the last choice is that all of the BPs are not sitting around waiting to see if our immunotherapy works. They have their own scientists and their new science (ie gene therapy). Another tool that they have is the relationship with FDA, lobbyists, all the sites and the investigators. They can buy them to work on their studies rather than ours. Little PPHM is swimming with the sharks and I just hope that they realize that.